Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell-Enriched DLI with or without DUK-CPG-001 Post-Transplant
NCT02452697Phase 2Active, not recruiting
- Start
- Jun 2016
- Primary completion
- Jul 2022
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of DUK-CPG-001 in myeloid malignancies and lymphoid malignancies. Primary endpoints: Progression-Free Survival Rate at 1 year and Number of Participants With Unacceptable Toxicity at 100 days. Started Jun 2016; status: active, not recruiting.
02
Drugs
DUK-CPG-001
03
Conditions
myeloid malignancieslymphoid malignancies
Beyond the preview
Go deeper on NCT02452697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452697.